Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Beckley Psytech Announces Partnership With Empatica in Latest Step of Digital Strategy, Designed to Deliver
A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT
Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules Robust Portfolio of Psychedelic-Inspired Molecules
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with
Lexston Announces a Memorandum of Understanding to Collabborate on Psychedelics Research and Development With Alvarius
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical
Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates Preclinical data demonstrated efficacy
Congress to Vote on Psychedelics Research Amendments for Active Military Members The US government is
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its
Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved Safety
